Loading
Cardiovascular Disease and Adiposity / Cancer, Lipids, and Metabolism / Chemotherapy-induced Cardiotoxicity and Mitigation · Journal article
Cardio-oncology · September 7, 2026
Raises a question worth testing. It does not answer one.
This narrative review synthesizes evidence for a bidirectional relationship between cardiovascular disease and cancer, proposing that CVD may promote tumor progression through cardiac secretion of tumor-potentiating factors, immune reprogramming, and microbiome dysbiosis. The authors identify heart failure biomarkers with potential associations across cancer types but do not provide clinical outcome data or causal evidence to support mechanistic claims or guide clinical practice.
Narrative review with biomarker literature analysis. Populations with cardiovascular disease phenotypes (atherosclerosis, hypertension, myocardial infarction, atrial fibrillation, heart failure) and their association with cancer incidence and mortality; animal models..
Multiple epidemiological studies across diverse CVD phenotypes (atherosclerosis, hypertension, myocardial infarction, atrial fibrillation, heart failure) show higher cancer incidence and mortality. Animal experimentation demonstrates mechanistic links between cardiac injury and exacerbated cancer progression. Proposed mechanisms include cardiac secretion of tumor-potentiating proteins and extracellular vesicles, immune reprogramming, and heart failure–associated gut microbiome dysbiosis.
Multiple epidemiological studies across diverse CVD phenotypes (atherosclerosis, hypertension, myocardial infarction, atrial fibrillation, heart failure) show higher cancer incidence and mortality.
The review suggests that CVD status should be considered in cancer risk stratification and that understanding heart-to-tumor signaling may inform prevention or therapeutic strategies in integrated cardio-oncology care. However, the evidence remains mechanistic and observational; prospective clinical trials are needed before practice changes are warranted.
A narrative review synthesizing epidemiological observations, animal mechanistic data, and biomarker analysis to propose bidirectional CVD–cancer relationships; lacks prospective clinical evidence or causal proof.
As stated by the source record.
The review suggests that CVD status should be considered in cancer risk stratification and that understanding heart-to-tumor signaling may inform prevention or therapeutic strategies in integrated cardio-oncology care. However, the evidence remains mechanistic and observational; prospective clinical trials are needed before practice changes are warranted.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
In recent years, the field of Cardio-Oncology has expanded beyond its traditional focus on cancer therapy–related cardiotoxicity. Growing evidence now supports a bidirectional relationship between cardiovascular disease (CVD) and cancer, in which CVD may promote tumor progression. Multiple epidemiological studies across diverse CVD phenotypes—including atherosclerosis, hypertension, myocardial infarction, atrial fibrillation and heart failure (HF)—point towards higher cancer incidence and mortality, extending beyond shared risk factors and pathophysiological pathways. Furthermore, animal experimentation has provided mechanistic clues linking cardiac injury to exacerbated cancer progression. Proposed mechanisms include cardiac secretion of tumor‑potentiating proteins and small extracellular vesicles, immune reprogramming and HF-associated gut microbiome dysbiosis. Notably, the impact of CVD on tumor progression appears cancer‑type-specific and may vary across tumor models, underscoring biological heterogeneity in heart-to-tumor crosstalk. In this review, we provide an overview of epidemiological and mechanistic evidence linking CVD to increased tumor growth. Additionally, we performed an analysis of literature-reported chronic HF biomarkers and their association with cancer. This analysis identified a subset of HF biomarkers with strong associations across multiple cancer types, highlighting potential molecular mediators of CVD-induced oncogenic signaling. Collectively, current evidence from epidemiological, experimental and computational data indicates a complex biological and potentially causal relationship between CVD and cancer, involving multiple mechanisms. Advancing mechanistic understanding may improve oncological risk stratification in CVD populations, guide the development of targeted strategies to disrupt heart-to-tumor signaling and strengthen the foundation for integrated Cardio-Oncology care.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.